Abeona Therapeutics Inc. buy dimontalban
Start price
24.10.22
/
60%
€3.80
Target price
24.10.23
€7.00
Performance (%)
18.42%
End price
29.10.22
€4.50
Summary
This prediction ended on 29.10.22 with a price of €4.50. The BUY prediction by dimontalban finished with a performance of 18.42%. dimontalban has 60% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Abeona Therapeutics Inc. | 39.869% | 39.869% | 52.530% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% |
According to dimontalban what are the pros and cons of Abeona Therapeutics Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Leading role in innovation
Some uniques
Known brand
Fair valuation
Top Rating
Standard Investments for future growth
Very capable Management
Very good company culture
Differentiated customer and product portfolio
Growths faster than the competition
Sustainability is very important
Stable Large shareholder and/or long term investor
Top 10 in its market
Very Future proof/growth oriented business model
Cons
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Very low/no dividend yield expected
High risks in the balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
negative Cash Flow expected
High risks for its business
Significant cyclical dependencies